Sulfonyl pyrrolidines, method for producing the same and their use as drugs

1. A compound of the formula Ia:

wherein:

R1 is selected from (C 1 -C 6 )-alkyl, where one or more hydrogens in the alkyl radical may be replaced by fluorine; phenyl, (C 1 -C 8 )-alkylene-phenyl, heterocyclyl, (C 1 -C 8 )-alkylene-heterocyclyl, where the phenyl or heterocycle radical may be substituted one or more times by a substituent selected from F, Cl, Br, NO 2 , COO—(C 1 -C 6 )-alkyl, (C 1 -C 6 )-alkylene-O—(C 1 -C 6 )-alkyl, OCF 3 , (C 1 -C 6 )-alkyl, CO—(C 1 -C 6 )-alkyl, phenyl, SCF 3 , and SF 5 ;

and the heterocycle is selected from the group consisting of thiophene, quinoline, oxadiazole, isoxazole and pyridine and may be fused to a benzene ring;

R2 is selected from phenyl and heterocycle, where the phenyl or heterocycle radical may be substituted one or more times by a substituent selected from F, Cl, Br, NO 2 , COO—(C 1 -C 6 )-alkyl, (C 1 -C 6 )-alkylene-O—(C 1 -C 6 )-alkyl, OCF 3 , (C 1 -C 6 )-alkyl, CO—(C 1 -C 6 )-alkyl, phenyl, SCF 3 , and SF 5 and the heterocycle is selected from the group consisting of dioxole, tetrahydrofuran, isoxazole, oxazine, thiophene and pyridine and may be fused to a benzene ring; and

R3 and R4 are, independently of one another, selected from H, F, Cl, Br, NO 2 , COO—(C 1 -C 6 )-alkyl, (C 1 -C 6 )-alkylene-O—(C 1 -C 6 )-alkyl, OCF 3 , (C 1 -C 6 )-alkyl, CO—(C 1 -C 6 )-alkyl, phenyl, SCF 3 , and SF 5 ;

where the compound of the following formula is excluded

or a physiologically tolerated salt thereof.

2. A medicament comprising at least one compound of claim 1 in combination with at least one carrier or an excipient.

3. A medicament comprising at least one compound of claim 1 and at least one other active ingredient.

4. The medicament as claimed in claim 3 , wherein the other active ingredient is selected from antidiabetics, hypoglycemic active ingredients, HMGCoA reductase inhibitors, cholesterol absorption inhibitors, PPAR gamma agonists, PPAR alpha agonists, PPAR alpha/gamma agonists, fibrates, MTP inhibitors, bile acid absorption inhibitors, CETP inhibitors, polymeric bile acid adsorbents, LDL receptor inducers, ACAT inhibitors, antioxidants, lipoprotein lipase inhibitors, ATP-citrate lyase inhibitors, squalene synthetase inhibitors, lipoprotein(a) antagonists, lipase inhibitors, insulins, sulfonylureas, biguanides, meglitinides, thiazolidinediones, α-glucosidase inhibitors, active ingredients which act on the ATP-dependent potassium channel of the beta cells, CART agonists, NPY agonists, MC4 agonists, orexin agonists, H3 agonists, TNF agonists, CRF agonists, CRF BP antagonists, urocortin agonists, β3 agonists, MSH (melanocyte-stimulating hormone) agonists, CCK agonists, serotonin reuptake inhibitors, mixed serotoninergic and noradrenergic compounds, 5HT agonists, bombesin agonists, galanin antagonists, growth hormones, growth hormone-releasing compounds, TRH agonists, uncoupling protein 2 or 3 modulators, leptin agonists, DA agonists (bromocriptine, Doprexin), lipase/amylase inhibitors, PPAR modulators, RXR modulators or TR-β agonists or amphetamines.

5. A method for increasing HDL in the blood of a patient which comprises administering to said patient an effective amount of at least one compound of claim 1 .

6. A method for the treatment of arteriosclerotic manifestations which comprises administering to a patient in need thereof an effective amount of at least one compound of claim 1 .

7. A process for producing a medicament comprising, as the active ingredient, a compound of claim 1 , which comprises mixing the active ingredient with a pharmaceutically suitable carrier and converting this mixture into a form suitable for administration.